

दो अंक एक साथ

संग्रहणीय अंक

14 जनवरी, 2026

125 रुपए

इंडिया टुडे



9 770971 537270 3

50 वर्ष

भारत के
पुनर्निर्माण की कथा

1975-2025

अग्रिम सप्ताह के लिए प्रत्येक शनिवार को प्रकाशित; एतपीसी दिल्ली-आराएमएम-दिल्ली-110006 से प्रत्येक शनिवार और सोमवार को प्रेषित; कुल पन्नों की संख्या 346 (आवरण सहित) वर्ष 40; अंक: 06

RNI NO. 45823/1986 REGISTRATION NO. DL(DS)-02/MIP/2025-26-27, DL(ND)-11/6042/2024-25-26; LICENSED TO POST WPP NO U(C)-31/2024-26; FARIDABAD/46/2026-28 www.indiatodayhindi.com



INSIDE LORDS MARK INDUSTRIES' BLUEPRINT TO MAKE INDIA A GLOBAL HEALTHCARE HUB

In the evolving narrative of India's healthcare transformation, few enterprises embody ambition and innovation as distinctly as Lords Mark Industries Ltd. (LMIL). Over the past 27 years, the company has transitioned from a diversified manufacturing enterprise into one of India's most forward-looking MedTech groups — an organisation that fuses scientific research, engineering precision, and national purpose to create globally competitive healthcare solutions.

At a moment when healthcare systems worldwide are striving to balance **affordability, access, and innovation**, LMIL is positioning India at the forefront of this transformation. Its expanding portfolio across **biotechnology, diagnostics, genomics, and medical devices** is reshaping how the world perceives Indian capability from low-cost production to high-value innovation.

Engineering a Vision Aligned with India's Healthcare Ambitions

LMIL-Renalyx's recent breakthrough — winning the licence to design and manufacture Class C, World's First AI-enabled smart hemodialysis systems and becoming the world's sixth CE-certified brand in this category, stands as a defining marker of India's accelerating MedTech capabilities. This achievement not only places the company in an elite global league but also signals the maturity of India's indigenous innovation in critical-care technology. LMIL's journey mirrors the country's broader aspiration to build a self-reliant MedTech hub

under the Make in India and Atmanirbhar Bharat missions. The company's singular clarity of purpose — using technology to democratize healthcare — has guided its investments for over a decade. Nearly all capital has been directed towards creating an integrated healthcare ecosystem powered by R&D, digital intelligence, and advanced manufacturing. Its facilities adhere to stringent global benchmarks including US FDA, ISO 13485:2016, WHO-GMP, and CDSCO certifications, enabling seamless access to highly regulated international markets.

This ecosystem-strengthening approach also led to LMIL securing US FDA registration in 2025 for its surgical consumables, orthopaedic supports, and hygiene range — placing it among a select group of Indian manufacturers trusted across the U.S., European, and Middle Eastern healthcare systems. Together, these milestones reflect not just regulatory compliance, but rising global confidence in India's ability to deliver precision-grade, scalable healthcare technology.



Sachidanand Upadhyay, MD & CEO

Healthcare Innovation as the Core Engine

While LMIL's diversification spans multiple industries, **healthcare has become the company's defining identity**. Its innovation roadmap encompasses diagnostics, MedTech, preventive health, and genomics — all directed toward creating a more predictive, data-led model of care.

The **Renalyx platform** is one of LMIL's most transformative initiatives — a connected, AI-driven kidney care ecosystem that integrates early disease detection, smart dialysis devices, and analytics-led monitoring. By focusing on accessibility and remote deployment, Renalyx addresses a critical gap in chronic kidney care, especially across India's underserved geographies.

In **genomic science**, LMIL's brand **One DNA** has emerged as a pioneer in **saliva-based genetic testing**, providing affordable insights into disease predispositions such as cancer, diabetes, and cardiovascular disorders. This shift from reactive to preventive medicine signals LMIL's commitment to personalizing healthcare for the next generation.

Collaborations with institutions such as **IIT Bombay** have further expanded LMIL's innovation bandwidth. Jointly developed technologies — including rapid tests for **sickle cell anaemia** and **oral cancer** using **optical spectroscopy** — reflect the company's capability to translate scientific research into scalable, field-ready medical solutions.

Manufacturing Strength as a Strategic Advantage

At the operational centre of LMIL's expansion lies its **integrated manufacturing complex in Dadra & Nagar Haveli** — a state-of-the-

art facility that unites five divisions producing surgical, orthopaedic, rehabilitation, and hygiene products. Fully automated machinery, advanced QC systems, and digital logistics tracking ensure real-time operational precision and global compliance.

This hub exemplifies **India's emergence as a MedTech manufacturing powerhouse** — combining efficiency with scientific rigour. Every process, from adhesive coating to sterilization validation, is benchmarked against international standards, ensuring products that meet the demands of both clinical precision and economic scalability.

Looking forward, LMIL is setting audacious targets. By **2027**, it plans to establish **Asia's largest biochemistry reagents plant**, followed by the continent's **largest medical device facility in 2028**. These projects represent not only capacity expansion but a vision to turn India into a **global export base for MedTech innovation**.

To support this phase of growth, LMIL is preparing for a **global capital raise** and a **dual listing on NASDAQ and BSE**, signalling its ambition to stand shoulder to shoulder with leading MedTech players from the U.S.A, Japan, and Germany.

Recognition and Global Impact

The world is taking notice. At the **Indo-European Business Forum (IEBF) 2025**, hosted at the **House of Lords, London**, LMIL was honoured with the **'Innovation in Diagnostic Devices' Award** — the first Indian diagnostics company to receive this distinction. The recognition underscored India's evolution from being a manufacturing support base to an **originator of cutting-edge MedTech innovations**.

Such international validation underscores a pivotal shift. Indian enterprises like LMIL are no longer just part of global supply chains; they are **redefining them**.

Sustainability and Purpose at Scale

Behind LMIL's industrial might is a deeply responsible business philosophy. The company's operations are guided by a **six-step Quality Excellence Framework**, ensuring every process — from raw material procurement to distribution — aligns with global sustainability and safety standards. Eco-efficient manufacturing, waste reduction, and **AI-driven logistics optimization** reflect a commitment to reducing the company's carbon footprint without compromising speed or scale. More importantly, LMIL's leadership sees **healthcare as a social mission**, where innovation is measured not merely by profit but by **human impact**.

The Decade Ahead: India's MedTech Vanguard

As LMIL deepens its international presence through **Lords Mark Global LLC (U.S.)** and expands across **South and Southeast Asia**, its trajectory is unmistakable — that of a company shaping the next phase of India's healthcare globalisation.

By combining **scientific depth, manufacturing precision, and purpose-driven execution**, LMIL is building more than a business empire; it's constructing the foundation for India's MedTech leadership in the global arena.

In doing so, **Lords Mark Industries LTD** is demonstrating that India's most valuable export in the coming decade won't just be technology — it will be **trust, quality, and innovation built for the world**.

